Zimpfer Matthew J. 4
4 · CNO Financial Group, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
CNO Financial GC Matthew Zimpfer Exercises Options, Sells Shares
What Happened
- Matthew J. Zimpfer, General Counsel of CNO Financial Group (CNO), exercised stock options and immediately sold the resulting shares. On 2026-02-17 he exercised 23,570 shares at $23.33 (cost $549,888) and sold 23,570 shares at a weighted average of $43.17 (proceeds $1,017,413). On 2026-02-18 he exercised 33,800 shares at $17.48 (cost $590,824) and sold 33,800 shares at a weighted average of $43.05 (proceeds $1,455,141). Total gross proceeds from the sales were about $2,472,554; total exercise cost was about $1,140,712.
Key Details
- Transaction dates & prices:
- 2026-02-17: exercised 23,570 shares @ $23.33; sold those 23,570 @ weighted avg $43.17 (sales ranged $42.94–$43.79).
- 2026-02-18: exercised 33,800 shares @ $17.48; sold those 33,800 @ weighted avg $43.05 (sales ranged $42.92–$43.28).
- Shares involved: 57,370 total (23,570 + 33,800).
- Shares owned after transaction: not specified in this Form 4.
- Footnotes: Sales were made pursuant to a Rule 10b5‑1 trading plan adopted June 9, 2025 (F1). Sale price ranges and the availability of per‑trade detail are noted (F2, F3). Vesting history for the exercised options is provided (F4, F5).
- Filing timing: Form 4 was filed 2026-02-18 covering transactions on 2026-02-17 and 2026-02-18 (appears timely).
Context
- These transactions are option exercises followed by immediate open‑market sales (a form of cashless exercise). The Form 4 also reports derivative dispositions at $0 for the same share counts — commonly reported when shares are surrendered to cover exercise costs or tax withholding. Sales done under a prearranged 10b5‑1 plan are generally considered routine and do not by themselves indicate the insider’s view of the company.
Insider Transaction Report
Form 4
Zimpfer Matthew J.
General Counsel
Transactions
- Exercise/Conversion
Common Stock
2026-02-17$23.33/sh+23,570$549,888→ 331,507 total - Sale
Common Stock
[F1][F2]2026-02-17$43.17/sh−23,570$1,017,413→ 307,937 total - Exercise/Conversion
Common Stock
2026-02-18$17.48/sh+33,800$590,824→ 341,737 total - Sale
Common Stock
[F1][F3]2026-02-18$43.05/sh−33,800$1,455,141→ 307,937 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
[F4]2026-02-17−23,570→ 0 totalExercise: $23.33Exp: 2028-02-21→ Common Stock (23,570 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
[F5]2026-02-18−33,800→ 0 totalExercise: $17.48Exp: 2029-02-19→ Common Stock (33,800 underlying)
Footnotes (5)
- [F1]Shares sold pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2025.
- [F2]Reflects the weighted average sale price. Shares were sold at prices ranging from $42.94 per share to $43.79 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
- [F3]Reflects the weighted average sale price. Shares were sold at prices ranging from $42.92 per share to $43.28 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
- [F4]One-half of the stock options vested and became exercisable on February 21, 2020, and one-half vested and became exercisable on February 21, 2021.
- [F5]One-half of the stock options vested and became exercisable on February 19, 2021, and one-half vested and became exercisable on February 19, 2022.
Signature
Heidi M. Krings, Attorney-in-Fact|2026-02-18